Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Rediagnosis of Lung Cancer as NUT Midline Carcinoma Based on Clues From Tumor Genomic Profiling.

Baras AS, Naidoo J, Hann CL, Illei PB, Reninger CW 3rd, Lauring J.

J Natl Compr Canc Netw. 2018 May;16(5):467-472. doi: 10.6004/jnccn.2017.7203.

PMID:
29752320
2.

GATA3 frameshift mutation promotes tumor growth in human luminal breast cancer cells and induces transcriptional changes seen in primary GATA3 mutant breast cancers.

Gustin JP, Miller J, Farag M, Rosen DM, Thomas M, Scharpf RB, Lauring J.

Oncotarget. 2017 Oct 20;8(61):103415-103427. doi: 10.18632/oncotarget.21910. eCollection 2017 Nov 28.

3.

Comparison of healthcare utilization and outcomes by gestational diabetes diagnostic criteria.

Lauring JR, Kunselman AR, Pauli JM, Repke JT, Ural SH.

J Perinat Med. 2018 May 24;46(4):401-409. doi: 10.1515/jpm-2017-0076.

PMID:
28753546
4.

Using cancer genomics to guide clinical decisions.

Burkard ME, Deming DA, Lauring J.

Cancer. 2017 Apr 15;123(8):1288-1291. doi: 10.1002/cncr.30640. Epub 2017 Mar 2. No abstract available.

5.

PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity.

Croessmann S, Wong HY, Zabransky DJ, Chu D, Rosen DM, Cidado J, Cochran RL, Dalton WB, Erlanger B, Cravero K, Button B, Kyker-Snowman K, Hurley PJ, Lauring J, Park BH.

Breast Cancer Res Treat. 2017 Apr;162(3):451-464. doi: 10.1007/s10549-017-4147-2. Epub 2017 Feb 11.

PMID:
28190247
6.

Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board.

Dalton WB, Forde PM, Kang H, Connolly RM, Stearns V, Gocke CD, Eshleman JR, Axilbund J, Petry D, Geoghegan C, Wolff AC, Loeb DM, Pratilas CA, Meyer CF, Christenson ES, Slater SA, Ensminger J, Parsons HA, Park BH, Lauring J.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.16.00046. Epub 2017 May 31.

7.

A Polycythemia Vera JAK2 Mutation Masquerading as a Duodenal Cancer Mutation.

Lee J, Axilbund J, Dalton WB, Laheru D, Watkins S, Chu D, Cravero K, Button B, Kyker-Snowman K, Waters I, Gocke CD, Lauring J, Park BH.

J Natl Compr Canc Netw. 2016 Dec;14(12):1495-1498.

PMID:
27956534
8.

Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer.

Parsons HA, Beaver JA, Cimino-Mathews A, Ali SM, Axilbund J, Chu D, Connolly RM, Cochran RL, Croessmann S, Clark TA, Gocke CD, Jeter SC, Kennedy MR, Lauring J, Lee J, Lipson D, Miller VA, Otto GA, Rosner GL, Ross JS, Slater S, Stephens PJ, VanDenBerg DA, Wolff AC, Young LE, Zabransky DJ, Zhang Z, Zorzi J, Stearns V, Park BH.

Clin Cancer Res. 2017 Jan 15;23(2):379-386. doi: 10.1158/1078-0432.CCR-16-1543. Epub 2016 Aug 3.

9.

Evolving Role of the Estrogen Receptor as a Predictive Biomarker: ESR1 Mutational Status and Endocrine Resistance in Breast Cancer.

Lauring J, Wolff AC.

J Clin Oncol. 2016 Sep 1;34(25):2950-2. doi: 10.1200/JCO.2016.68.4720. Epub 2016 Jul 5. No abstract available.

PMID:
27382095
10.

Visualizing the Impact of Art: An Update and Comparison of Current Psychological Models of Art Experience.

Pelowski M, Markey PS, Lauring JO, Leder H.

Front Hum Neurosci. 2016 Apr 26;10:160. doi: 10.3389/fnhum.2016.00160. eCollection 2016.

11.

Combined hormonal contraception use in reproductive-age women with contraindications to estrogen use.

Lauring JR, Lehman EB, Deimling TA, Legro RS, Chuang CH.

Am J Obstet Gynecol. 2016 Sep;215(3):330.e1-7. doi: 10.1016/j.ajog.2016.03.047. Epub 2016 Apr 5.

12.

US term stillbirth rates and the 39-week rule: a cause for concern?

Nicholson JM, Kellar LC, Ahmad S, Abid A, Woloski J, Hewamudalige N, Henning GF, Lauring JR, Ural SH, Yaklic JL.

Am J Obstet Gynecol. 2016 May;214(5):621.e1-9. doi: 10.1016/j.ajog.2016.02.019. Epub 2016 Feb 12.

PMID:
26880736
13.

Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton.

Hu H, Juvekar A, Lyssiotis CA, Lien EC, Albeck JG, Oh D, Varma G, Hung YP, Ullas S, Lauring J, Seth P, Lundquist MR, Tolan DR, Grant AK, Needleman DJ, Asara JM, Cantley LC, Wulf GM.

Cell. 2016 Jan 28;164(3):433-46. doi: 10.1016/j.cell.2015.12.042.

14.

Ki-67 is required for maintenance of cancer stem cells but not cell proliferation.

Cidado J, Wong HY, Rosen DM, Cimino-Mathews A, Garay JP, Fessler AG, Rasheed ZA, Hicks J, Cochran RL, Croessmann S, Zabransky DJ, Mohseni M, Beaver JA, Chu D, Cravero K, Christenson ES, Medford A, Mattox A, De Marzo AM, Argani P, Chawla A, Hurley PJ, Lauring J, Park BH.

Oncotarget. 2016 Feb 2;7(5):6281-93. doi: 10.18632/oncotarget.7057.

15.

Identification of small for gestational age by population-based and customized growth charts in newborns of obese and normal-weight primiparous women.

Lauring JR, Gupta M, Kunselman AR, Repke JT, Pauli JM.

J Matern Fetal Neonatal Med. 2016 Nov;29(21):3570-4. doi: 10.3109/14767058.2016.1139568. Epub 2016 Feb 29.

PMID:
26755451
16.

TMSB4Y is a candidate tumor suppressor on the Y chromosome and is deleted in male breast cancer.

Wong HY, Wang GM, Croessmann S, Zabransky DJ, Chu D, Garay JP, Cidado J, Cochran RL, Beaver JA, Aggarwal A, Liu ML, Argani P, Meeker A, Hurley PJ, Lauring J, Park BH.

Oncotarget. 2015 Dec 29;6(42):44927-40. doi: 10.18632/oncotarget.6743.

17.

Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity.

Yi KH, Lauring J.

Oncotarget. 2016 Jan 26;7(4):4241-51. doi: 10.18632/oncotarget.6648.

18.

HER2 missense mutations have distinct effects on oncogenic signaling and migration.

Zabransky DJ, Yankaskas CL, Cochran RL, Wong HY, Croessmann S, Chu D, Kavuri SM, Red Brewer M, Rosen DM, Dalton WB, Cimino-Mathews A, Cravero K, Button B, Kyker-Snowman K, Cidado J, Erlanger B, Parsons HA, Manto KM, Bose R, Lauring J, Arteaga CL, Konstantopoulos K, Park BH.

Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6205-14. doi: 10.1073/pnas.1516853112. Epub 2015 Oct 27.

19.

NDRG1 links p53 with proliferation-mediated centrosome homeostasis and genome stability.

Croessmann S, Wong HY, Zabransky DJ, Chu D, Mendonca J, Sharma A, Mohseni M, Rosen DM, Scharpf RB, Cidado J, Cochran RL, Parsons HA, Dalton WB, Erlanger B, Button B, Cravero K, Kyker-Snowman K, Beaver JA, Kachhap S, Hurley PJ, Lauring J, Park BH.

Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):11583-8. doi: 10.1073/pnas.1503683112. Epub 2015 Aug 31.

20.

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.

Chu D, Paoletti C, Gersch C, VanDenBerg DA, Zabransky DJ, Cochran RL, Wong HY, Toro PV, Cidado J, Croessmann S, Erlanger B, Cravero K, Kyker-Snowman K, Button B, Parsons HA, Dalton WB, Gillani R, Medford A, Aung K, Tokudome N, Chinnaiyan AM, Schott A, Robinson D, Jacks KS, Lauring J, Hurley PJ, Hayes DF, Rae JM, Park BH.

Clin Cancer Res. 2016 Feb 15;22(4):993-9. doi: 10.1158/1078-0432.CCR-15-0943. Epub 2015 Aug 10.

21.

Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes.

Cochran RL, Cidado J, Kim M, Zabransky DJ, Croessmann S, Chu D, Wong HY, Beaver JA, Cravero K, Erlanger B, Parsons H, Heaphy CM, Meeker AK, Lauring J, Park BH.

Oncotarget. 2015 Sep 22;6(28):25240-51. doi: 10.18632/oncotarget.4595.

22.

Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA.

Toro PV, Erlanger B, Beaver JA, Cochran RL, VanDenBerg DA, Yakim E, Cravero K, Chu D, Zabransky DJ, Wong HY, Croessmann S, Parsons H, Hurley PJ, Lauring J, Park BH.

Clin Biochem. 2015 Oct;48(15):993-8. doi: 10.1016/j.clinbiochem.2015.07.097. Epub 2015 Jul 31.

23.

Engineering targeted chromosomal amplifications in human breast epithelial cells.

Springer S, Yi KH, Park J, Rajpurohit A, Price AJ, Lauring J.

Breast Cancer Res Treat. 2015 Jul;152(2):313-21. doi: 10.1007/s10549-015-3468-2. Epub 2015 Jun 23.

24.

MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers.

Mohseni M, Cidado J, Croessmann S, Cravero K, Cimino-Mathews A, Wong HY, Scharpf R, Zabransky DJ, Abukhdeir AM, Garay JP, Wang GM, Beaver JA, Cochran RL, Blair BG, Rosen DM, Erlanger B, Argani P, Hurley PJ, Lauring J, Park BH.

Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17606-11. doi: 10.1073/pnas.1408650111. Epub 2014 Nov 24.

25.

Detection of cancer DNA in plasma of patients with early-stage breast cancer.

Beaver JA, Jelovac D, Balukrishna S, Cochran R, Croessmann S, Zabransky DJ, Wong HY, Toro PV, Cidado J, Blair BG, Chu D, Burns T, Higgins MJ, Stearns V, Jacobs L, Habibi M, Lange J, Hurley PJ, Lauring J, VanDenBerg D, Kessler J, Jeter S, Samuels ML, Maar D, Cope L, Cimino-Mathews A, Argani P, Wolff AC, Park BH.

Clin Cancer Res. 2014 May 15;20(10):2643-2650. doi: 10.1158/1078-0432.CCR-13-2933. Epub 2014 Feb 6.

26.

Human cell line model for cancer-associated KRAS noncoding SNP.

Lauring J.

Hum Mutat. 2014 Feb;35(2):v. doi: 10.1002/humu.22404. No abstract available.

PMID:
24415639
27.

PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.

Beaver JA, Gustin JP, Yi KH, Rajpurohit A, Thomas M, Gilbert SF, Rosen DM, Ho Park B, Lauring J.

Clin Cancer Res. 2013 Oct 1;19(19):5413-22. doi: 10.1158/1078-0432.CCR-13-0884. Epub 2013 Jul 25.

28.

The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.

Lauring J, Park BH, Wolff AC.

J Natl Compr Canc Netw. 2013 Jun 1;11(6):670-8. Review.

29.

Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation.

Wang GM, Wong HY, Konishi H, Blair BG, Abukhdeir AM, Gustin JP, Rosen DM, Denmeade SR, Rasheed Z, Matsui W, Garay JP, Mohseni M, Higgins MJ, Cidado J, Jelovac D, Croessmann S, Cochran RL, Karnan S, Konishi Y, Ota A, Hosokawa Y, Argani P, Lauring J, Park BH.

Cancer Res. 2013 Jun 1;73(11):3248-61. doi: 10.1158/0008-5472.CAN-12-1578. Epub 2013 Apr 11.

30.

Management of gestational hypertension - the impact of HYPITATa.

Pauli JM, Lauring JR, Stetter CM, Repke JT, Botti JJ, Ural SH, Ambrose A.

J Perinat Med. 2013 Jul;41(4):415-20. doi: 10.1515/jpm-2012-0179.

PMID:
23399585
31.

TORn in Two Over Breast Cancer Drug Resistance.

Lauring J, Park BH.

Oncology (Williston Park). 2013 Jan 15;27(1). pii: 168735. No abstract available.

32.
33.

The growth response to androgen receptor signaling in ERĪ±-negative human breast cells is dependent on p21 and mediated by MAPK activation.

Garay JP, Karakas B, Abukhdeir AM, Cosgrove DP, Gustin JP, Higgins MJ, Konishi H, Konishi Y, Lauring J, Mohseni M, Wang GM, Jelovac D, Weeraratna A, Sherman Baust CA, Morin PJ, Toubaji A, Meeker A, De Marzo AM, Lewis G, Subhawong A, Argani P, Park BH.

Breast Cancer Res. 2012 Feb 9;14(1):R27.

34.

NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.

Kuo AJ, Cheung P, Chen K, Zee BM, Kioi M, Lauring J, Xi Y, Park BH, Shi X, Garcia BA, Li W, Gozani O.

Mol Cell. 2011 Nov 18;44(4):609-20. doi: 10.1016/j.molcel.2011.08.042.

35.

BEAMing sheds light on drug resistance.

Lauring J, Park BH.

Clin Cancer Res. 2011 Dec 15;17(24):7508-10. doi: 10.1158/1078-0432.CCR-11-2556. Epub 2011 Nov 7.

36.

Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.

Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, Tahir K, Abukhdeir AM, Gustin JP, Cidado J, Wang GM, Cosgrove D, Cochran R, Jelovac D, Higgins MJ, Arena S, Hawkins L, Lauring J, Gross AL, Heaphy CM, Hosokawa Y, Gabrielson E, Meeker AK, Visvanathan K, Argani P, Bachman KE, Park BH.

Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):17773-8. doi: 10.1073/pnas.1110969108. Epub 2011 Oct 10.

37.

PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells.

Higgins MJ, Beaver JA, Wong HY, Gustin JP, Lauring JD, Garay JP, Konishi H, Mohseni M, Wang GM, Cidado J, Jelovac D, Cosgrove DP, Tamaki A, Abukhdeir AM, Park BH.

Cancer Biol Ther. 2011 Feb 1;11(3):358-67. Epub 2011 Feb 1.

38.

Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations.

Lauring J, Cosgrove DP, Fontana S, Gustin JP, Konishi H, Abukhdeir AM, Garay JP, Mohseni M, Wang GM, Higgins MJ, Gorkin D, Reis M, Vogelstein B, Polyak K, Cowherd M, Buckhaults PJ, Park BH.

Oncogene. 2010 Apr 22;29(16):2337-45. doi: 10.1038/onc.2009.516. Epub 2010 Jan 25.

39.

Knockin of mutant PIK3CA activates multiple oncogenic pathways.

Gustin JP, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP, Cosgrove D, Tamaki A, Konishi H, Konishi Y, Mohseni M, Wang G, Rosen DM, Denmeade SR, Higgins MJ, Vitolo MI, Bachman KE, Park BH.

Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2835-40. doi: 10.1073/pnas.0813351106. Epub 2009 Feb 5.

40.

Tamoxifen-stimulated growth of breast cancer due to p21 loss.

Abukhdeir AM, Vitolo MI, Argani P, De Marzo AM, Karakas B, Konishi H, Gustin JP, Lauring J, Garay JP, Pendleton C, Konishi Y, Blair BG, Brenner K, Garrett-Mayer E, Carraway H, Bachman KE, Park BH.

Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):288-93. Epub 2007 Dec 27.

41.

A PCR-based high-throughput screen with multiround sample pooling: application to somatic cell gene targeting.

Konishi H, Lauring J, Garay JP, Karakas B, Abukhdeir AM, Gustin JP, Konishi Y, Park BH.

Nat Protoc. 2007;2(11):2865-74.

PMID:
18007621
42.

The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.

Lauring J, Abukhdeir AM, Konishi H, Garay JP, Gustin JP, Wang Q, Arceci RJ, Matsui W, Park BH.

Blood. 2008 Jan 15;111(2):856-64. Epub 2007 Oct 17.

43.

Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation.

Konishi H, Karakas B, Abukhdeir AM, Lauring J, Gustin JP, Garay JP, Konishi Y, Gallmeier E, Bachman KE, Park BH.

Cancer Res. 2007 Sep 15;67(18):8460-7.

44.

A conserved transcriptional enhancer regulates RAG gene expression in developing B cells.

Hsu LY, Lauring J, Liang HE, Greenbaum S, Cado D, Zhuang Y, Schlissel MS.

Immunity. 2003 Jul;19(1):105-17.

45.
46.

Distinct factors regulate the murine RAG-2 promoter in B- and T-cell lines.

Lauring J, Schlissel MS.

Mol Cell Biol. 1999 Apr;19(4):2601-12.

47.

Immunocytochemical characterization of the high-affinity thiazide diuretic receptor in rabbit renal cortex.

Ellison DH, Biemesderfer D, Morrisey J, Lauring J, Desir GV.

Am J Physiol. 1993 Jan;264(1 Pt 2):F141-8.

PMID:
8430824

Supplemental Content

Loading ...
Support Center